As of 10:30 AM on the 15th, SK is trading at 238,000 KRW, up 2.81% from the previous day. The trading volume is 387,142 shares, which is 53.72% of the previous day's volume. SK is known as the holding company of the SK Group.

On July 10, Hana Financial Investment researchers Choi Jung-wook and Kang Seung-won stated, "1) Besides SK Biopharm, the IPO possibilities for SK Siltron and SK Pharmteco are high, 2) new investments are expected to secure mobility-based assets including negotiations to acquire AirAsia shares, 3) DPS is expected to continue rising regardless of earnings due to investment recovery, which is a factor that can be expected to drive further rebound, 4) in the mid-to-long term, there is also anticipation of NAV expansion following the transfer of SK Hynix subsidiaries, and 5) if SK Biopharm is early included in major indices such as KOSPI 200, the SK Biopharm supply and demand effect will clearly transfer to SK." They set SK's target price at 320,000 KRW.

Over the past five days, individual investors have net bought 166,992 shares of SK, while foreigners and institutions have net bought 152,653 shares and net sold 321,742 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing